KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
CORALVILLE, Iowa, April 05, 2016 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Needham & Company’s 15th Annual Healthcare Conference being held in New York, NY, April 12 - 13, 2016.
Details of KemPharm's presentation are as follows:
Date: Tuesday, April 12, 2016
Time: 10:40 AM (ET)
Location: Westin NY Grand Central Hotel; New York, NY
The presentation will be webcast and available on the Investor Relations section of the Company's website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Jim Heins Cooney Waters Unlimited 212-886-2221 [email protected]
